Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
Retinoblastoma, Extraocular
About this trial
This is an interventional treatment trial for Retinoblastoma, Extraocular focused on measuring retinoblastoma, central metastases, intrathecal Chemotherapy
Eligibility Criteria
Inclusion Criteria:
- The pathological diagnosis was retinoblastoma. According to the IRSs (International retinoblastoma staging system) staging system, the stage was IVB
- CSF tumor cells on cytology, or radiographic evidence of NM on MRI scans and histologic diagnosis of systemic malignancy needed
- KPS≥60%
- Adequate bone marrow and organ function
- The parents signed the informed consent and were willing to accept the treatment and follow-up.
Exclusion Criteria:
- 1.Eye diseases other than retinoblastoma
- The eyes were infected within 30 days before screening
- There was a history of surgery and / or unhealed wound within 1 month before enrollment .
- Those who have allergic reaction or allergic history to chemotherapeutic drugs.
- Infectious diseases requiring oral, intramuscular or intravenous administration.
- Patients with systemic immune diseases.
- Active disseminated intravascular coagulation.
- Abnormal coagulation function.
- Abnormal bone marrow and organ function.
- Uncontrollable clinical problems.
- The researchers believe that those who need to be excluded.
Sites / Locations
- Fudan Eye & ENT HospitalRecruiting
Arms of the Study
Arm 1
Experimental
intrathecal chemotherapy in patients with central metastases
Systemic chemotherapy and intrathecal chemotherapy are performed every 3 weeks. After three treatment cycles, the treatment response is comprehensively evaluated including cerebrospinal fluid, intracranial and orbital tumors. If necessary, local radiotherapy and arterial interventional chemotherapy are performed for local solid tumors. Cerebrospinal fluid is detected in each treatment cycle. If RB tumor cells still exist in cerebrospinal fluid, chemotherapy and intrathecal chemotherapy are continued until the end event. If cerebrospinal fluid was negative, intrathecal chemotherapy is supplemented for another 2 cycles with a total of 6 cycles of systemic chemotherapy. The patients are followed up after treatment.